Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 28,800 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Medication Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of BMS-986165 on the Blood Levels of Metformin

NCT04671953
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986165, Metformin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 23, 2026, 3:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.

NCT04909853
View directory record Official record
Conditions
Renal Impairment
Interventions
PF-07321332/ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
5
States / cities
Tustin, California • Miami, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 23, 2026, 3:02 AM EDT
Completed Phase 4 Interventional

Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients

NCT00752037
View directory record Official record
Conditions
HIV Infections
Interventions
lopinavir/ritonavir and raltegravir
Drug
Lead sponsor
Saint Michael's Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 23, 2026, 3:02 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

NCT05627245
View directory record Official record
Conditions
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Follicular Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Follicular Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
Interventions
Belinostat, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Pharmacokinetic Study, Positron Emission Tomography and Computed Tomography Scan, Tazemetostat
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Sacramento, California • New Haven, Connecticut • Fairway, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 23, 2026, 3:02 AM EDT
Terminated Phase 1 Interventional

A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer

NCT02819999
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Rovalpituzumab Tesirine, Cisplatin, Etoposide
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Aurora, Colorado • Denver, Colorado • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 23, 2026, 3:02 AM EDT
Completed Not applicable Interventional

Promoting Alcohol Treatment Engagement Post-hospitalization

NCT05338151
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Brief Negotiated Interview (BNI), BNI+facilitated provision of MAUD, Brief Negotiated Interview BNI+facilitated provision of MAUD+CBT4CBT
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 23, 2026, 3:02 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Excipient Effect on Drug Absorption in Humans

NCT04534153
View directory record Official record
Conditions
The Impact of Excipients on Drug Absorption
Interventions
Fexofenadine Hydrochloride without sodium lauryl sulfate, Fexofenadine Hydrochloride with sodium lauryl sulfate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 23, 2026, 3:02 AM EDT
Completed Phase 2 Interventional Results available

Lung-MAP S1400K: c-MET Positive

NCT03574753
View directory record Official record
Conditions
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC V7
Interventions
ABBV-399
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 23, 2026, 3:02 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

A Trial of Cervidil for Outpatient Pre-induction of Cervical Ripening

NCT03806231
View directory record Official record
Conditions
Induction of Labor Affected Fetus / Newborn
Interventions
Outpatient Dinoprostone 10mg, Inpatient Dinoprostone 10 mg
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
St. George, Utah
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 23, 2026, 3:02 AM EDT
Terminated Phase 1 Interventional

The Seven Trial: Exploiting the Unfolded Protein Response

NCT06076837
View directory record Official record
Conditions
Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic
Interventions
Botensilimab, Balstilimab, Chloroquine Phosphate, Celecoxib, Nab paclitaxel, Gemcitabine, Cisplatin
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 23, 2026, 3:02 AM EDT
Not yet recruiting Phase 4 Interventional

OMT for Adhesive Capsulitis

NCT07497737
View directory record Official record
Conditions
Adhesive Capsulitis of the Shoulder, Frozen Shoulder
Interventions
Intra-articular Injection, Osteopathic Manipulative Therapy (OMT)
Drug · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Beachwood, Ohio • Westlake, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 3:02 AM EDT
Recruiting Phase 1Phase 2 Interventional

Breakthrough - T1DM and Chronic Kidney Disease

NCT07592000
View directory record Official record
Conditions
Diabete Type 1, Chronic Kidney Disease
Interventions
Tegoprubart, Islet Cell Transplant
Drug · Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
2
States / cities
Miami, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 23, 2026, 3:02 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

NCT03104400
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Adalimumab, Upadacitinib, Placebo to Upadacitinib, Placebo to Adalimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
1,705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
114
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 23, 2026, 3:02 AM EDT
Completed Phase 2 Interventional Results available

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

NCT02890992
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
alirocumab SAR236553 (REGN727), statins, ezetimibe, cholestyramine, fenofibrate, omega-3 fatty acids, nicotinic acid
Drug
Lead sponsor
Sanofi
Industry
Eligibility
8 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
St Louis, Missouri • Charlotte, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 23, 2026, 3:02 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

NCT05050136
View directory record Official record
Conditions
Primary Biliary Cholangitis, PBC
Interventions
Volixibat, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
44
States / cities
Coronado, California • Los Angeles, California • Sacramento, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 23, 2026, 3:02 AM EDT
Completed Phase 2 Interventional Results available

Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer

NCT00246571
View directory record Official record
Conditions
Breast Neoplasms
Interventions
SU011248, Chemotherapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
77
States / cities
Corona, California • Fullerton, California • Glendora, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Oct 23, 2026, 3:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pre-op Cognitive Behavior Therapy to Decrease Chronic Post-Surgical Pain in TKA

NCT04814992
View directory record Official record
Conditions
Chronic Post-Surgical Pain
Interventions
Computer-Assisted Preoperative CBT Intervention (PAINTrainer)
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
22 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
4
States / cities
Philadelphia, Pennsylvania • Radnor, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 23, 2026, 3:02 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

NCT05947500
View directory record Official record
Conditions
Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Locally Advanced Merkel Cell Carcinoma, Metastatic Merkel Cell Carcinoma, Refractory Merkel Cell Carcinoma, Unresectable Merkel Cell Carcinoma
Interventions
Avelumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Tuvusertib
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
50
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 23, 2026, 3:02 AM EDT
Completed Not applicable Interventional

Addressing Disparities in Diabetes Care

NCT06643611
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Continuous Glucose Monitor, Usual Care
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 23, 2026, 3:02 AM EDT
Active, not recruiting Phase 1 Interventional

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

NCT06177171
View directory record Official record
Conditions
BRCA1 Mutation, BRCA2 Mutation, BRCA Mutation, PALB2 Gene Mutation, Checkpoint Kinase 2 Gene Mutation, ATM Gene Mutation
Interventions
Olaparib, ASTX727
Drug
Lead sponsor
Varun Monga, MBBS
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 3:02 AM EDT
Completed Phase 1 Interventional

Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors

NCT00003144
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
amifostine trihydrate, cisplatin, gemcitabine hydrochloride
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Oct 23, 2026, 3:02 AM EDT
Completed Phase 4 Interventional Results available

Impact of Local Anesthetic Wound Infiltration on Postoperative Pain Following Cesarean Delivery

NCT02829944
View directory record Official record
Conditions
Pain
Interventions
Ropivacaine, Ketorolac, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 23, 2026, 3:02 AM EDT
Completed Phase 2 Interventional Results available

Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy

NCT04415944
View directory record Official record
Conditions
Ovarian Epithelial Cancer Stage I, Ovarian Epithelial Cancer Stage II, Ovarian Epithelial Cancer Stage III, Stage I Fallopian Tube Cancer, Stage II Fallopian Tube Cancer, Stage III Fallopian Tube Cancer, Peritoneal Carcinoma
Interventions
Second look laparoscopy reassessment surgery (SLLRS), HIPEC with Carboplatin, FACT-O Quality of Life Questionnaire
Procedure · Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 23, 2026, 3:02 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Safety Study of AQUAVAN® (Fospropofol Disodium) Injection for Sedation During Minor Surgical Procedures.

NCT00327392
View directory record Official record
Conditions
Procedural Sedation
Interventions
AQUAVAN® (fospropofol disodium) Injection
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
15
States / cities
Phoenix, Arizona • Jacksonville, Florida • Louisville, Kentucky + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 23, 2026, 3:02 AM EDT